Cargando…

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies

BACKGROUND: Zibotentan (ZD4054) is a specific endothelin A (ET(A)) receptor antagonist being investigated for the treatment of prostate cancer. As zibotentan is eliminated by renal and metabolic routes, clearance may be reduced in patients with hepatic or renal impairment, leading to greater drug ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomkinson, Helen, Kemp, John, Oliver, Stuart, Swaisland, Helen, Taboada, Maria, Morris, Thomas
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070638/ https://www.ncbi.nlm.nih.gov/pubmed/21414193 http://dx.doi.org/10.1186/1472-6904-11-3

Ejemplares similares

Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence
por: Morris, C D, et al.
Publicado: (2005)

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment
por: Mercier, Anne-Kristina, et al.
Publicado: (2023)

Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).
por: Judson, I., et al.
Publicado: (1998)

4054 Telemedicine Infectious Diseases Consultation in Rural Hospitals: Feasibility, Acceptability, Appropriateness, and Implementation
por: Burnham, Jason P., et al.
Publicado: (2020)

Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial
por: Stern, Edward P., et al.
Publicado: (2022)

Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial
por: Morrow, Andrew J, et al.
Publicado: (2020)

Zibotentan, an Endothelin A Receptor Antagonist, Prevents Amyloid-β-Induced Hypertension and Maintains Cerebral Perfusion
por: Palmer, Jennifer C., et al.
Publicado: (2020)

A Novel CACNA1A Nonsense Variant [c.4054C>T (p.Arg1352(⁎))] Causing Episodic Ataxia Type 2
por: Lance, Sean, et al.
Publicado: (2018)

Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects
por: Li, Guofei, et al.
Publicado: (2018)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study
por: Cong, Duanduan, et al.
Publicado: (2022)

ZD6474 – clinical experience to date
por: Heymach, J V
Publicado: (2005)

Pharmacokinetics and Tolerability of Inhaled Umeclidinium and Vilanterol Alone and in Combination in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Trial
por: Hu, Chaoying, et al.
Publicado: (2015)

A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
por: Tayo, Bola, et al.
Publicado: (2019)

An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis
por: Devereux, Graham, et al.
Publicado: (2016)

Production of the Bioactive Compounds Violacein and Indolmycin Is Conditional in a maeA Mutant of Pseudoalteromonas luteoviolacea S4054 Lacking the Malic Enzyme
por: Thøgersen, Mariane S., et al.
Publicado: (2016)

Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue
por: Monks, N R, et al.
Publicado: (2001)

Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP‐5862, in patients with B‐cell malignancies and in healthy subjects using a population pharmacokinetic approach
por: Edlund, Helena, et al.
Publicado: (2021)

The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan
por: Veenit, Vandana, et al.
Publicado: (2023)

A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
por: Trivedi, Ashit, et al.
Publicado: (2022)

The Higgs as a portal to the hidden sector via an analysis of $H\to Zd_d Z_d \to 4l$ using the ATLAS detector
por: Unwuchola, D A
Publicado: (2015)

Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial
por: Galloway, Gantt P, et al.
Publicado: (2005)

Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open‐label trial
por: Farkas, Mark Kristof, et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
por: Bækdal, Tine A., et al.
Publicado: (2018)

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
por: Granhall, Charlotte, et al.
Publicado: (2018)

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency
por: Santamaria, Manuel, et al.
Publicado: (2022)

Pharmacokinetics of Tramadol and Celecoxib in Japanese and Caucasian Subjects Following Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label Study
por: Dooner, Helen, et al.
Publicado: (2018)

A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment
por: Csonka, Denes, et al.
Publicado: (2016)

Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects
por: Hanboonkunupakarn, Borimas, et al.
Publicado: (2014)

Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects
por: Sun, Haiying, et al.
Publicado: (2016)

Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open‐label, phase I study in healthy subjects
por: Tachibana, Masaya, et al.
Publicado: (2023)

Pharmacokinetics and bioequivalence of sunitinib and Sutent(®) in Chinese healthy subjects: an open-label, randomized, crossover study
por: Wang, Yanli, et al.
Publicado: (2023)

Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency
por: Santamaria, Manuel, et al.
Publicado: (2022)

A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects
por: Cheng, Yiming, et al.
Publicado: (2023)

A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
por: Ermer, James, et al.
Publicado: (2016)

Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study
por: Fassio, Angelo, et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects
por: O’Donnell, John, et al.
Publicado: (2019)

Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma
por: Shen, J, et al.
Publicado: (2013)

The accumulation of rare-earth yttrium ions by Penicillium sp. ZD28
por: Wang, Weiying, et al.
Publicado: (2020)

Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
por: Wiebe, Sabrina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cqkanndvnk8unkp6mnl2jv2cbl